Candel Therapeutics, Inc.

Candel Therapeutics, Inc. announced the appointment of Mark Sims as Chief Commercial Officer, effective July 6, 2026. Mr. Sims will lead the commercial strategy and launch readiness for aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk localized prostate cancer. This appointment supports the planned BLA submission in Q4 2026 and a potential 2027 launch, targeting approximately 65,000 US patients annually. Mr. Sims brings over 25 years of oncology commercial experience to the role.

Candel Therapeutics, Inc. entered into an employment agreement with its Chief Financial Officer, Charles Schoch, on June 12, 2026. The agreement outlines the terms of his continued at-will employment, maintaining his annual base salary of $468,600 and eligibility for an annual bonus targeted at 40% of his base salary. The agreement also details severance provisions, including nine months of base salary plus target annual bonus, and up to nine months of COBRA health coverage continuation, upon termination without cause or for good reason. Additionally, all time-based equity awards will fully accelerate if his employment is terminated under specific conditions related to a change in control.

Candel Therapeutics announced extended follow-up data from its pivotal Phase 3 trial of aglatimagene besadenovec (CAN-2409) for localized prostate cancer. The data confirmed a statistically significant 39% improvement in prostate cancer-specific disease-free survival compared to placebo, with a median follow-up of 58 months. The study also showed consistent clinical benefits across secondary and exploratory endpoints, including a 90% reduction in time to metastasis in intermediate-risk patients. The company plans to submit a Biologics License Application to the FDA in Q4 2026.

Candel Therapeutics reported a net loss of $8.9 million for the first quarter of 2026, a significant shift from the net income of $7.4 million in the same period last year. Despite the loss, the company substantially strengthened its financial position, with cash and cash equivalents rising to $194.8 million, primarily due to $93.5 million in net proceeds from a public offering of common stock in February 2026. The company continues to incur significant operating losses and expects to require additional funding to finance its operations, but believes existing resources will fund planned operations for at least 12 months.

Candel Therapeutics announced its Q1 2026 financial results and provided a corporate update, highlighting plans to submit a Biologics License Application (BLA) for aglatimagene in localized prostate cancer in Q4 2026. The company also established a commercial partnership with EVERSANA for a potential U.S. launch and plans to initiate a pivotal Phase 3 clinical trial for aglatimagene in NSCLC in Q2 2026. Financially, Candel reported a net loss of $8.9 million for Q1 2026, but ended the quarter with $194.8 million in cash, expected to fund operations into Q1 2028.

Candel Therapeutics, Inc. announced that its President and CEO, Paul Peter Tak, will present and participate in one-on-one meetings with investors at two upcoming conferences. He will speak at the Stifel 2026 Virtual Targeted Oncology Forum on May 20, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026. Candel Therapeutics is a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies for cancer, with lead product candidates aglatimagene besadenovec (CAN-2409) and linoserpaturev (CAN-3110) in clinical development.

Candel Therapeutics, Inc. announced it will host a webcast and conference call on May 15, 2026, to discuss extended follow-up data from its pivotal Phase 3 clinical trial of aglatimagene besadenovec (CAN-2409). The trial focuses on patients with intermediate- to high-risk localized prostate cancer. The discussion will follow an oral plenary presentation of these data at the American Urological Association (AUA) 2026 Annual Meeting and will feature insights from prominent prostate cancer specialists.

Candel Therapeutics, Inc. announced that its Compensation Committee granted stock options for an aggregate of 29,400 shares of common stock to two new employees on April 30, 2026. The options, with an exercise price of $6.18 per share, were issued under the Company's 2025 Inducement Plan. These awards are intended to incentivize the new employees and will vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments.

Candel Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 23, 2026. Stockholders will vote on the election of four Class II directors and the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date for voting is April 24, 2026, and proxy materials are being made available online.

Candel Therapeutics, Inc. (CADL) announced a product commercialization agreement with EVERSANA to support the potential U.S. launch of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk, localized prostate cancer. EVERSANA will provide a broad suite of integrated commercialization services, joining IDEA Pharma in pre-commercial workstreams. This collaboration establishes a partner-led commercial model designed to leverage world-class capabilities while maintaining Candel's financial flexibility and scientific focus, ahead of a planned BLA submission in Q4 2026.